Trial record 15 of 51 for:    "hidradenitis suppurativa" OR "acne inversa"

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02904902
Recruitment Status : Active, not recruiting
First Posted : September 19, 2016
Last Update Posted : January 25, 2018
Information provided by (Responsible Party):

Brief Summary:
This study investigates efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with moderate to severe Hidradenitis Suppurativa (HS).

Condition or disease Intervention/treatment Phase
Hidradenitis Suppurativa Drug: Adalimumab Phase 3

Detailed Description:
Prior to initiation of this study, global Phase 2b study and pivotal Phase III studies were completed in the Western countries and market authorization of adalimumab was approved in US and European Union (EU) for the treatment of subjects with HS. The differences between this study and global studies include sample size, study design, duration, and race.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa
Actual Study Start Date : September 6, 2016
Primary Completion Date : September 1, 2017
Estimated Study Completion Date : May 8, 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Adalimumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Patients receiving adalimumab
Subcutaneous injection of dose A at Week 0 (Baseline) and dose B at Week 2 followed by weekly dosing of dose C from Week 4
Drug: Adalimumab
Sub-cutaneous Injection
Other Name: Humira

Primary Outcome Measures :
  1. Proportion of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 [ Time Frame: At Week 12 ]
    HiSCR is defined as at least a 50% reduction in the total abscess and inflammatory nodule count (AN count) with no increase in abscess count and no increase in draining fistula count relative to Baseline.

Secondary Outcome Measures :
  1. Proportion of participants achieving AN count of 0, 1, or 2 at Week 12 [ Time Frame: At Week 12 ]
    The proportion of participants with AN counts lowered to 0, 1, or 2 at Week 12 among participants with AN counts >=3 at Baseline

  2. Proportion of participants achieving at least 30% reduction and at least 1 unit reduction from Baseline in Patient's Global Assessment of Skin Pain (NRS30) - at worst at Week 2 among participants with Baseline NRS >=3 [ Time Frame: Week 0 (baseline) up to Week 12 ]
    The patient's Global Assessment of Skin Pain Numeric Rating Scale was used to assess the worst skin and average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours".

  3. Change in modified Sartorius scale [ Time Frame: Week 0 (baseline) and Week 12 ]
    The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodule (2 points for each); abscesses (4 points); fistulas (4 points); scar (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated buy normal skin (yes-0 point; no-6 points) The total Sartorius Scale is the sum of the 12 regional scores. Scale range will be 0 to infinite and larger scale represents higher severity of HS.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant must have a diagnosis of hidradenitis suppurativa (HS);
  • Participant must have any HS symptom at least 6 months prior to Baseline;
  • HS lesions must be present in at least 2 distinct anatomic areas, one of which must be Hurley Stage II or Hurley Stage III;
  • Participant must have stable HS for at least 2 months (60 days) prior to Screening and also at the Baseline visit;
  • Participant must have a total AN count of greater than or equal to 3 at the Baseline visit.

Exclusion Criteria:

  • Prior treatment with adalimumab or other anti-tumor necrosis factor (TNF) therapy or participation in adalimumab trial;
  • Any other active skin lesion or condition that may interfere with assessment of HS;
  • Participants received antibiotic treatment for HS within 28 days prior to the Baseline visit other than those allowed per protocol. Participant on permitted oral antibiotic treatment (doxycycline or minocycline only) for HS who have not been on a stable dose for at least 28 days prior to the Baseline visit;
  • Participants received prescription topical therapies for the treatment for HS within 14 days prior to the Baseline visit;
  • Participants received systemic non-biologic therapies with potential therapeutic impact for HS less than 28 days prior to the Baseline visit;
  • Participants received oral concomitant analgesics (non-opioids and opioids) for HS-related pain within 14 days prior to the Baseline visit.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02904902

Nagoya City University Hospital
Nagoya-shi, Aichi, Japan, 467-8602
Fukuoka University Hospital
Fukuoka-shi, Fukuoka, Japan, 814-0180
Kurume University Hospital
Kurume-shi, Fukuoka, Japan, 830-0011
Takagi Dermatological Clinic
Obihiro-shi, Hokkaido, Japan, 080-0013
University of the Ryukyus Hospital
Nakagami-gun, Okinawa, Japan, 903-0215
National Hospital Organization Osaka National Hospital
Osaka-shi, Osaka, Japan, 540-0006
Tokai University Hachioji Hospital
Hachiōji-shi, Tokyo, Japan, 192-0032
Tokyo Medical University Hospital
Shinjuku-Ku, Tokyo, Japan, 160-0023
Sponsors and Collaborators
Study Director: AbbVie Inc. AbbVie

Additional Information:
AbbVie  This link exits the site

Responsible Party: AbbVie Identifier: NCT02904902     History of Changes
Other Study ID Numbers: M15-573
First Posted: September 19, 2016    Key Record Dates
Last Update Posted: January 25, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by AbbVie:
japanese participants

Additional relevant MeSH terms:
Hidradenitis Suppurativa
Sweat Gland Diseases
Skin Diseases
Skin Diseases, Bacterial
Bacterial Infections
Skin Diseases, Infectious
Anti-Inflammatory Agents
Antirheumatic Agents